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Abstract 
Background: Male breast cancer is a rare event, accounting for approximately 1% of all breast carcinomas. Although 
men with breast cancer had poorer survival when compared with women, data on prognosis principally derive from 
retrospective studies and from extrapolation of female breast cancer series. We reported the case of a very long sur-
vival patient.
Case presentation: A caucasian 42-year-old man underwent radical mastectomy with axillary dissection for breast 
cancer in 1993. Pathologic stage was pT4pN0M0 infiltrating ductal carcinoma of right breast without lymph nodes 
metastases. Biological characterization was not available. He received adjuvant treatment with chemotherapy, six 
cycles of cyclophosphamide, methotrexate and fluorouracil, then endocrine therapy with tamoxifen for 5 years and 
complementary radiotherapy. Then he began clinical-instrumental follow up. In May 1996, a computed tomography 
scan showed multiple lung metastases. Hereafter he received several oncologic treatment including seven chemo-
therapy and five endocrine therapy lines with two re-challenge of endocrine therapy. In October 2007 further lung 
progression was showed and a biopsy was performed to characterize the disease. Histological examination con-
firmed breast cancer metastases, immunohistochemistry showed positive staining for estrogen receptor, negative for 
progesterone receptor and human epithelial growth factor receptor 2, proliferative index was 21%. In April 2013, bone 
disease progression was evident and he received radiant treatment to sacral spine. In May 2014 an off-label treatment 
with exemestane and everolimus combination was approved by Ethics Committee of the Marche Region. The patient 
received treatment for 3 months with evident clinical benefit to subcutaneous lesions of the chest wall that were not 
visible nor palpable on physical examination after 1 month of treatment.
Conclusion: That is the case of long survival male breast cancer patient with luminal B subtype and no BRCA muta-
tions. He achieved higher progression free survival with endocrine therapy creating the rationale for last line treat-
ment with everolimus and exemestane combination. Attending conclusive results from ongoing studies, everolimus 
and exemestane should not be used routinely in male metastatic breast cancer patients, but taking into account for 
selected cases. At the best of our knowledge, this is the first case of male beast cancer treated with exemestane and 
everolimus combination.
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Background
Male breast cancer (MBC) is a rare event, accounting 
for approximately 1% of all breast carcinomas and less 
than 1% of all male cancers [1–3]. Recent data by The 
International Agency for Research on Cancer, a division 
of the World Health Organization, demonstrated the 
global incidence of MBC stands at nearly 8000 cases. For 
Europe, this equates to 3750 cases of MBC [4]. In 2014 in 
the United States, 2360 cases were estimated, while the 
lifetime risk of men getting breast cancer is 1 in 1000 [1]. 
Open Access
BMC Research Notes
*Correspondence:  zelmira.ballatore@gmail.com 
Clinica di Oncologia Medica e Centro Regionale di Genetica Oncologica, 
Università Politecnica delle Marche, AOU Ospedali Riuniti-Ancona, 
Ancona, Italy
Page 2 of 6Ballatore et al. BMC Res Notes  (2016) 9:497 
These figures are significantly lower (<1%) than the inci-
dence of breast cancer (BC) in women, which represents 
11.6% of the global cancer incidence in 2014 [5].
Men tend to present 5  years later than women do, 
commonly in the seventh decade [6, 7]. MBC incidence 
seems increasing and in the absence of formal epidemio-
logical studies, reasons for the apparent rise could only 
be speculated [8]. A large population-based study of 
2537 men with breast cancer, analyzed from the National 
Cancer Institute’s Surveillance, Epidemiology and End 
Results (SEER) database, reported that over a 25  year 
period (1973–1998) the incidence of MBC increased sig-
nificantly from 0.86 to 1.08 per 100,000 population in the 
United States [9].
MBC prognosis is reported to be poorer than female 
BC one, even if data mainly derived from retrospec-
tive studies and from extrapolation of female BC series. 
Endocrine therapy seems to be effective and many studies 
report that aromatase inhibitors (AIs) may be an effective 
and safe treatment option for hormonal receptor (HR) 
positive, metastatic male breast cancers progressing on 
tamoxifen [10–14].
Unfortunately, not all patients respond to first-line 
endocrine therapy (primary or de novo resistance), and 
even patients who have a response will eventually relapse 
(acquired resistance).
Everolimus, an mTOR inhibitor, in combination with 
exemestane demonstrated a 6-month improvement in 
women with resistance to non-steroidal aromatase inhib-
itors [15].
In clinical practice, this could be good rationale for the 
everolimus combination use to overcome the resistance, 
also in MBC, unfortunately until now there are no data in 
this setting of patients.
We report the case of a very long survival male breast 
cancer patient who was affected by hormone-sensitive 
disease and received an off label combination treatment 
with everolimus plus exemestane, as a 13th line of treat-
ment, approved by Ethics Committee of the Marche 
Region (CERM).
According to our country’s legislation, since it was a 
retrospective study, with no direct patient involvement, 
the ethical approval and patients consent for the study 
were not required (Official Gazette No. 72 of March 26, 
2012). The medical record was reviewed to find data on 
patient’s medical history and a written informed consent 
was obtained from the patient’s next of kin for publica-
tion of this Case Report and any accompanying images. 
A copy of the written consent is available for review by 
Editor in Chief of this journal.
Case presentation
We describe the case of a 42-year-old Caucasian man 
who was diagnosed with BC in 1993. The patient 
reported a case of BC in his family, anyway without a 
medical history of risk factors for BC. In June 1993, he 
underwent to a radical mastectomy with axillary lym-
phadenectomy; histopathological examination con-
firmed infiltrating ductal carcinoma of the right breast 
with poor cellular differentiation, G3, large areas of 
necrosis, infiltration of subcutaneous tissue and mus-
cular involvement. Biological characterization was not 
available. The final pathologic stage was pT4pN0(0/12)
M0. He was given adjuvant treatment with six cycles 
of CMF (cyclophosphamide 600  mg/m2, methotrexate 
40  mg/m2, fluorouracil 600  mg/m2) administered day 
1–8, every 4  weeks, endocrine therapy with tamoxifen 
20  mg daily for 5  years and complementary radiother-
apy on the chest wall. In May 1996, during follow-up, 
a computed tomography (CT) scan revealed multiple 
lung metastases. Hereafter the patient started a first-
line weekly paclitaxel chemotherapy, obtaining a partial 
response. In March 1997, paclitaxel was stopped because 
of lung metastases progression and an endocrine ther-
apy with megestrol was administered until January 
2000 when it was discontinued for a vein thrombosis 
and switch to exemestane. In January 2001, a new CT 
showed a further progression of disease (PD). Epirubicin 
and docetaxel were administered until June 2001 when a 
further lung progression was revealed. Thus, patient was 
given letrozole, 2.5  mg daily, until January 2002 when 
his lung disease progressed. A course of vinorelbine 
was started but in December 2002 chemotherapy was 
interrupted for PD and a re-challenge with megestrol 
produced a partial response until October 2007 when 
disease progressed again. We performed a lung biopsy to 
confirm etiology and histological examination was posi-
tive for BC metastases, immunohistochemistry showed 
positive staining for the estrogen receptor (ER) 99%, 
negative for progesterone receptor (PR) 0, 1% and for 
herceptest (1+). Ki67 was 21%. In October 2007, a re-
challenge was done with tamoxifen, previously used in 
the adjuvant setting, and in May 2008, with a stable dis-
ease and a poor compliance, it was suspended. In Janu-
ary 2009, lung metastases progressed and capecitabine 
was prescribed observing stable disease for 2 years.
From February 2011 until March 2013, a metronomic 
combination of cyclophosphamide and methotrexate 
was administered. In April 2013, bone and nodes metas-
tases were diagnosed, then he received bone palliative 
radiotherapy.
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In May 2013 carboplatin and zoledronic acid were 
given, but a progressive disease was observed in October 
2013 (lung, subcutaneous metastases). A biopsy of skin 
lesions confirmed breast cancer metastases. We com-
menced eribuline for a total of six cycles with no clini-
cal benefit. Consequently, we interrupted therapy for 
PD with pulmonary lymphangitis, pulmonary thrombo-
embolism and significant deterioration of the patient’s 
clinical condition (Eastern Cooperative Oncology Group 
Performance Status, ECOG PS 2).
In May 2014 an off-label treatment with everoli-
mus (EVE) and exemestane (EXE) was requested and 
approved by Ethics Committee of the Marche Region 
(CERM). After one month of treatment with everolimus, 
it was possible to highlight the complete response of the 
skin lesions had almost completely disappeared and were 
no longer palpable on physical examination (Fig. 1, Pan-
els 1.1, 1.2). Whereas, a partial response of the other skin 
lesions located in the right mammary region is evident. 
At the start of the combined treatment, there were ulcer-
ative lesions which healed (Fig. 1, Panels 1.3, 1.4).
Unfortunately, this treatment lasted for 4 months only 
due to the deterioration of the patient’s clinical condi-
tion. Dyspnea was, in fact, evident, at the start of the 
fifth cycle. The patient complained of coughing and fur-
ther worsening of his ECOG PS. A chest radiography 
was done which was strongly suggestive of pneumonitis 
(Fig. 2a) then we interrupted treatment with everolimus 
and exemestane and we started him on systemic ster-
oid therapy, bronchodilators and supplemental oxygen. 
A new X-ray was done 10  days after cessation of treat-
ment and highlights an improvement in the pneumonitis 
(Fig. 2b).
Despite this improvement in his breathing symp-
toms, his clinical condition worsened. He became even 
more cachectic and sadly expired a month later. Table 1 
resumed patient’s medical history.
In 1996, the patient underwent genetic counseling 
and genetic testing which was negative for BRCA1 and 
BRCA2 gene mutation.
Conclusions
Although the hormonal environment in male patients dif-
fers from that in female patients, AIs may play a key role 
in the treatment of male BC patients since in men, 80% 
of circulating estrogens derived from peripheral aroma-
tization of testicular and adrenal androgens, with direct 
production from the testes accounting for the remain-
ing 20%. Several studies carried out in healthy men have 
demonstrated that administration of non-steroidal AIs 
causes a significant decrease in plasma estrogen. How-
ever, data about the impact of AIs on estrogen plasma 
levels in MBC patients and their clinical efficacy are still 
lacking [10–14]. Recently, Doyen et al. demonstrated that 
aromatase inhibition leads to a significant decrease of 
estrogen level in MBC patients [16]. However, baseline 
estrogen levels are higher in men than in postmenopausal 
women because of a higher level of peripheral androgens 
and AIs do not seem able to inhibit the testicular produc-
tion of estrogen, which account for 20% of the circulat-
ing estrogen. In healthy men, AIs caused a significant 
increase of LH and FSH [17–19]. These results lead to 
hypothesize that suppression of estrogen production in 
male patients by monotherapy using AIs may be subopti-
mal respect to the combination of AIs with the analogue 
LH–releasing hormone [16, 20]. Aromatase inhibitors are 
widely used for treating metastatic male breast cancer 
patients but, in this setting, their use is not substantiated 
by prospective clinical trials, rather driven by supposed 
similarities existing with breast cancer in postmenopau-
sal women [21].
BOLERO-2 trial results demonstrated that the combina-
tion of everolimus and exemestane increases the efficacy 
compared with exemestane in terms of progression-free 
survival (4–6  months) in a patient population of post-
menopausal, hormone receptor positive, advanced breast 
cancer patients up to one prior chemotherapy treatment 
[15]. To the best of our knowledge, this is the second case 
of male breast cancer treated with everolimus. Recently, 
Fig. 1 1.1, 1.2 Complete response of subcutaneous lesion near the 
port –à-cath. 1.3, 1.4 Partial response of ulcerative skin lesion which 
eventually healed
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Kattan J reported the first case of a 74-year-old man who 
had relapsed after 4 years of adjuvant tamoxifen therapy. 
Eight subsequent cycles of vinorelbine and capecitabine 
produced a moderate partial response. Tamoxifen was 
reintroduced to maintain the outcome, whereas in an 
attempt to reverse hormone-resistance, tamoxifen and 
everolimus were combined [22].
Although heavily pretreated, our patient responded 
very well to endocrine therapy so, despite his poor clini-
cal condition, we proposed a new endocrine line with 
exemestane and everolimus as an off label treatment rul-
ing out the option of tamoxifen everolimus combination, 
because of his recent pulmonary thromboembolism.
Besides, today, it’s also uncertain if exemestane is the 
optimal treatment to adding with everolimus. Ongo-
ing trials have been evaluated the role of everolimus to 
reverse hormone-resistance in combination with dif-
ferent endocrine agents as ER antagonist (e.g., Fulves-
trant) or as monotherapy. On this basis, we are waiting 
for results of a phase II trial to evaluate the efficacy of 
everolimus as monotherapy in the treatment of women 
with ER+ metastatic BC [23].
In our experience, that is the case of a highly pretreated 
patient with very good response to endocrine therapy and 
who precociously stopped the everolimus plus exemes-
tane treatment because of the development of pneumoni-
tis. It has already been documented that about 15–20% of 
female BC patients treated with everolimus and exemes-
tane combination have non-infectious pneumonitis. 
From BOLERO-2 trial results, approximately one-quarter 
of events (grade ≥2) occurred within the first 12 weeks 
(cumulative risk, 5%). Cumulative risks of pneumoni-
tis (grade ≥2) in the EVE + EXE arm were 10 and 16% 
at 24 and 48  weeks, respectively. Among patients with 
grade 3 pneumonitis in the EVE + EXE arm, 80% expe-
rienced resolution to grade ≤1, typically following dose 
interruption/reduction, after a median of 3.8 weeks and 
in case administering systemic steroids, and supplemen-
tal oxygen if patient’s symptoms are moderate to severe 
[24–26]. The pulmonary toxicities incidence in patients 
affected by BC are similar to those affected by metastatic 
renal cell carcinoma and pancreatic neuroendocrine 
tumors which are treated with everolimus respectively in 
2nd/3th line and in case of unresectable, locally advanced 
or metastatic disease [26].
That is the case of long survival male BC patient with 
luminal B subtype and no BRCA mutations. Further-
more, our patient achieved higher PFS with endocrine 
therapy than chemotherapy creating the rationale for last 
line of treatment with everolimus and exemestane com-
bination. He immediately reported an important clinical 
benefit, as it could be highlighted by the resolution of 
skin lesions after one month of treatment. Exemestane 
and everolimus combination offered a partial response 
with the severe adverse event pneumonitis leading to 
treatment interruption shortly before the patient expired.
Attending conclusive results from ongoing studies, 
the combination should not be used routinely in male 
Fig. 2 a At the start of the fifth cycle dispnea was evident. A chest radiography was done which was strongly suggestive of pneumonitis then we 
interrupted treatment with everolimus exemestane and we started him on systemic therapy steroid, bronchodilators and supplemental oxygen. b 
A new chest radiography was taken 10 days after cessation of treatment and highlights an improvement in the pneumonitis
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metastatic BC patients. It might be taking into account 
for highly selected cases, as male patients with HR posi-
tive BC with good response and long time to progres-
sion to preceding endocrine lines and especially with 
very good performance status since the possible severe 
adverse events.
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